Una perspectiva racional y vigente del uso de los inhibidores de la enzima monoamina-oxidasa tipo B (IMAOs-B) en el tratamiento de la enfermedad de Parkinson

Background: the agitans paralysis described the early 1800S but it was not until the end of the same century when coined the eponymous of Parkinson's disease; however, there is evidence that this disease there since ancient times. Since it is still an incurable disease, from then until the date your treatment remains a challenge, despite the therapeutic resources now available. Objective: to realize a short historical review about Parkinson's disease treatments and update analysis about Monoamine Oxidase Inhibitors type B in Parkinson's disease management. Material y Methods: We made a bibliographic search by internet into Goglee, Pubmed and Ovid using following key words: Parkinson's disease, Parkinson's disease options of managements, Monoamine Oxidase Inhibitors type B in Parkinson's disease, selegiline & rasagiline and Parkinson's disease. We got more of 90,000 papers, form them we chose just complete historical treatment compilation and medical articles with evidence label I or Meta analysis. At end 33 papers were chosen. Conclusions: We made different treatments synopsis used for Parkinson's disease, the beginning of levodopa use and Monoamine Oxidase Inhibitors type B in Parkinson's disease update management.